Scientific Programme
Thursday, 20 November 2025
Virtual
15:00 – 15:10 CET
Welcome and IntroductionOliver Schnell (Munich, Germany)
15:10 – 16:15 CET
New Horizons in Cardiovascular, Kidney and Metabolic CareChairs: Jennifer Green (Durham, NC, USA), John McMurray (Glasgow, UK)
15:10 – 15:25
Progress in Heart Failure and the Growing Intersection of Cardiac and Kidney DiseaseScott Solomon (Boston, MA, USA)
15:25 – 15:45
SURPASSing Previous Boundaries: Incretin Mimetics and Cardiorenal OutcomesStefano del Prato (Pisa, Italy)
15:45 – 16:00
The Aldosterone Pathway Revisited: Novel Approaches in Hypertension ManagementMichel Azizi (Paris, France)
16:00 – 16:15
Discussion
16:15 – 17:30 CET
From Study to Guideline to Practice: Making Clinical Evidence WorkChairs: Helena Rodbard (Rockville, MD, USA), Frank Tacke (Berlin, Germany)
16:15 – 16:30
Perspectives of the Guideline Workshop (1) Obesity: New Opportunities for Network Meta-AnalysesArnav Agarwal (Hamilton, Canada)
16:30 – 16:45
Perspectives of the Guideline Workshop (2) Implementation of Guidelines at National Level: Perspectives of the European Renal Association (ERA)Christoph Wanner (Wuerzburg, Germany)
16:45 – 17:00
Breaking Barriers in Hard to Control Hypertension: Key Insights for PractitionersKamlesh Khunti (Leicester, UK)
17:00 – 17:15
Putting Person-Centered Care into Practice: What Matters to Patients with Chronic Liver DiseaseMarko Korenjak (Brussels, Belgium)
17:15 – 17:30
Discussion
17:30 – 17:45 CET
Break
17:45 – 18:30 CET
Policy Session: Transforming Cardiometabolic Health: Advancing Science, Integrated Care and PolicyChair: Oliver Schnell (Munich, Germany)
17:45 – 17:55
EU Policies to Improve Cardiovascular HealthMEP Romana Jerković (Brussels, Belgium)
17:55 – 18:05
Towards an Inclusive EU CV PlanChantal Mathieu (Leuven, Belgium)
18:05 – 18:15
Cardiovascular Health: How to Transition to National ProgressDirk Müller-Wieland (Aachen, Germany)
18:15 – 18:20
CommentaryDenis Ballwieser (Munich, Germany)
18:20 – 18:30
Panel Discussion: Targeted Initiatives for Cardiovascular Prevention
18:30 – 19:30 CET
Hellmut Mehnert AwardChairs: Rury Holman (Oxford UK), Eberhard Standl (Munich, Germany)
18:30 – 18:40
Introduction of the AwardRury Holman (Oxford UK)
18:40 – 18:45
Laudation and Presentation of AwardeeRury Holman (Oxford, UK)
18:45 – 19:25
The Discovery of Multi-Receptor Drugs: The end of obesity and type 2 diabetes?Matthias Tschöp (Munich, Germany)
19:25 – 19:30
ClosingRury Holman (Oxford UK), Eberhard Standl (Munich, Germany)
19:30 – 20:15 CET
Oral Presentations – Part 1Chairs: Dipesh Patel (London, UK), Nikolaos Papanas (Alexandroupolis, Greece)
OP 1: Prediabetes Remission and Long-Term Risk of Cardiovascular Death, Heart Failure Hospitalization, and All-Cause MortalityAndreas Birkenfeld (Tuebingen, Germany)
OP 2: Clinical association of diabetes mellitus and heart failure with metabolic dysfunction-associated steatotic liver diseaseKateryna Pivtorak (Vinnytsia, Ukraine)
OP 3: Relationship between undiagnosed diabetes, cardiovascular events and mortality in acute coronary syndrome patients enrolled in the STRONG-MI registryFaisal Aziz (Graz, Austria)
OP 4: Influence of Diabetes Mellitus on Thrombosis in Branch Retinal Vein OcclusionMarianne Shahsuvaryan (Yerevan, Armenia)
20:15 CET
Closing Day 1Oliver Schnell (Munich, Germany)
Friday, 21 November 2025
Virtual
08:45 – 09:30 CET
Advancing Early Detection and Preventive Strategies in Type 1 DiabetesChair:Thomas Danne (Lisbon, Portugal)
08:45 – 09:00
C-Peptide as a Surrogate Parameter for Residual Beta Cell Function in Type 1 Diabetes and its Potential Clinical RoleColin M. Dayan (Cardiff, UK)
09:00 – 09:15
Targeting Autoimmunity in Type 1 Diabetes: Emerging Disease-Modifying StrategiesChantal Mathieu (Leuven, Belgium)
09:15 – 09:30
Discussion
09:30 – 10:30 CET
Continuous Monitoring: Current and Emerging PerspectivesChair: Julia Mader (Graz, Austria)
09:30 – 09:45
The Heartbeat of Glucose: CGM’s Role in Cardiovascular Outcomes in DiabetesTadej Battelino (Ljubljana, Slovenia)
09:45 – 10:00
Building CGM Expertise: Recommendations for Education and PracticePratik Choudhary (Leicester, UK)
10:00 – 10:15
Continuous Ketone Monitoring: A New Era in Metabolic ManagementSusanne Reger-Tan (Bad Oeynhausen, Germany)
10:15 – 10:30
Discussion
10:30 - 10:40
Break
10:40 - 10:55
Satellite Symposium
See Further, Act Smarter: How AI Is Transforming Diabetes CareJohn Pemberton (Birmingham, UK)Supported by Roche Diagnostics International Ltd.
See Further, Act Smarter: How AI Is Transforming Diabetes CareJohn Pemberton (Birmingham, UK)Supported by Roche Diagnostics International Ltd.
10:55 - 11:00
Break
11:00 – 12:00 CET
The Silent Link: Diabetes and Chronic Kidney DiseaseChairs: Rury Holman (Oxford, UK), Paola Fioretto (Padua, Italy)
11:00 – 11:15
Kidney Protection in Type 1 Diabetes: Are Non-Steroidal MRAs the Next Step?Hiddo Heerspink (Groningen, The Netherlands)
11:15 – 11:30
SGLT2 Inhibitors and Non-Steroidal MRAs: Combining Forces for Cardiorenal ProtectionJohannes Mann (Munich, Germany)
11:30 – 11:45
Future Directions in the Treatment of Chronic Kidney DiseaseParminder Judge (Oxford, UK)
11:45 - 12:00
Discussion
12:00 – 13:00 CET
Integrated Approaches in Heart Failure TherapyChairs: Naoki Sato (Kawaguchi, Japan), Henrike Arfsten (Vienna, Austria)
12:00 – 12:15
SGLT2 Inhibitors – Changing the Game in Heart Failure TreatmentNikolaus Marx (Aachen, Germany)
12:15 – 12:30
Changing Landscape in HFpEF: New Therapeutic StrategiesPardeep Jhund (Glasgow, UK)
12:30 – 12:45
Emerging Treatment Strategies in HFrEFGiuseppe Rosano (London, UK)
12:45 – 13:00
Discussion
13:00 – 13:30 CET
Break
13:30 – 15:00 CET
Multidisciplinary Strategies in Obesity and Metabolic Liver DisordersChairs: Matthias Blüher (Leipzig, Germany), Linong Ji (Beijing, China)
13:30 – 13:45
Obesity 2025 – State of the Art in Diagnosis and TherapyTimothy Garvey (Birmingham, AL, USA)
13:45 – 14:00
One Target Is Not Enough? Novel GLP-1-Based Treatment ApproachesSean Wharton (Toronto, Canada)
14:00 – 14:15
Discussion
14:15 – 14:30
The Liver in Distress: Managing Obesity-Related MASLDElisabetta Bugianesi (Turin, Italy)
14:30 – 14:45
Nutrition Under Incretin TherapyAndreas Pfeiffer (Berlin, Germany)
14:45 – 15:00
Discussion
15:00 – 15:30 CET
The Global Alliance for Cardio-Kidney-Metabolic Care – Holistic Approaches to Improve Clinical CareChairs: Stephan Jacob (Villingen-Schwenningen, Germany), Andrew Krentz (London, UK)
15:00 – 15:15
Beyond LDL Lowering: Managing the Residual Risk in ASCVDPeter Libby (Boston, MA, USA)
15:15 – 15:30
Why Do We Need to Establish Cardio-Metabolic-Renal Care and Beyond?Robert Eckel (Denver, CO, USA)
15:30 – 16:30 CET
Practical Implementation in Primary Care: A Hands-On SessionChairs: Pinar Topsever (Istanbul, Turkey), Baruch Itzhak (Haifa, Israel)
15:30 – 15:45
Why Early Diagnosis Matters, and How to Put It into Practice in Chronic Kidney DiseaseAna María Cebrián Cuenca (Murcia, Spain)
15:45 – 16:00
Supporting Patient Adherence – Practical Strategies for Clinical PracticeKatharine Barnard-Kelly (Hampshire, UK)
16:00 – 16:15
Translating Guidelines into Practice: A Heart Failure Nurse’s PerspectiveEkaterini Lambrinou (Limassol, Cyprus)
16:15 – 16:30
Discussion
16:30 – 16:45
Break
16:45 – 17:45 CET
Industry’s Perspective – Panel DiscussionOliver Schnell (Munich, Germany)
17:45 – 18:30 CET
Oral Presentations – Part 2Chair: Banshi Saboo (Ahmedabad, India)
OP 5: A Time In Range of 70% Attenuates the Senescence-Inducing and Pro-Inflammatory Effects of HyperglycemiaRosalba La Grotta (Milan, Italy)
OP 6: Monitoring ketone levels continuously during a 7-day fastNina Jendrike (Ulm, Germany)
OP 7: Routine Biopsychosocial Care Is Practical and AchievableKatharine Barnard-Kelly (Fareham, UK)
OP 8: Pharmacist-Led Consultations for Continuous Glucose Monitoring Users: Knowledge, Confidence, and Opportunities to Support Diabetes Management and OutcomesAnastasija Levkina (Vilnius, Lithuania)
18:30 – 18:45 CET
Abstract Award and ClosingOliver Schnell (Munich, Germany)
The eCME accreditation for German HCPs is kindly supported by Abbott, AstraZeneca, Boehringer Ingelheim, Dexcom, Eli Lilly, Roche, Sanofi, Bayer and Wörwag. (10,500€)